title: [Dasatinib-related pneumonia? An example of pharmacovigilance survey].
authors.affiliation: Service de médecine interne, CHU Côte-de-Nacre, avenue Côte-de-Nacre, 14000 Caen, France. Electronic address: alexandra.audemard@hotmail.fr.
authors.forename: A
authors.initials: A
authors.lastname: Audemard
authors.affiliation: Centre régional de pharmacovigilance, CHU Côte-de-Nacre, 14000 Caen, France.
authors.forename: B
authors.initials: B
authors.lastname: de la Gastine
authors.affiliation: Service d'hématologie, CHU Côte-de-Nacre, 14000 Caen, France.
authors.forename: S
authors.initials: S
authors.lastname: Chantepie
authors.affiliation: Service de pneumologie, CHU Côte-de-Nacre, 14000 Caen, France.
authors.forename: H
authors.initials: H
authors.lastname: Verger
authors.affiliation: Service d'hématologie, CHU Côte-de-Nacre, 14000 Caen, France.
authors.forename: A C
authors.initials: AC
authors.lastname: Gac
authors.affiliation: Service de pneumologie, CHU Côte-de-Nacre, 14000 Caen, France.
authors.forename: E
authors.initials: E
authors.lastname: Bergot
authors.affiliation: Service d'hématologie, CHU Côte-de-Nacre, 14000 Caen, France.
authors.forename: O
authors.initials: O
authors.lastname: Reman
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001752:Blast Crisis / Q000150:complications / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D000069439:Dasatinib; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D060735:Pharmacovigilance; D011014:Pneumonia / Q000139:chemically induced* / Q000000981:diagnostic imaging; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011994:Recombinant Proteins; D013844:Thiazoles; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D000069585:Filgrastim; D000069439:Dasatinib; D008727:Methotrexate
keywords: Chronic myeloid leukemia; Dasatinib; Drug-induced pneumonitis; Interstitial pneumonia; Leucémie myéloïde chronique; Pneumopathie interstitielle; Pneumopathie médicamenteuse